9EWM
Mpro from SARS-CoV-2 with R4Q R298Q double mutations
9EWM の概要
| エントリーDOI | 10.2210/pdb9ewm/pdb |
| 分子名称 | Non-structural protein 11 (1 entity in total) |
| 機能のキーワード | sars-cov-2, protease, mpro, antiviral protein |
| 由来する生物種 | Homo sapiens (human) |
| タンパク質・核酸の鎖数 | 1 |
| 化学式量合計 | 33147.75 |
| 構造登録者 | |
| 主引用文献 | Lis, K.,Plewka, J.,Menezes, F.,Bielecka, E.,Chykunova, Y.,Pustelny, K.,Niebling, S.,Garcia, A.S.,Garcia-Alai, M.,Popowicz, G.M.,Czarna, A.,Kantyka, T.,Pyrc, K. SARS-CoV-2 M pro oligomerization as a potential target for therapy. Int.J.Biol.Macromol., 267:131392-131392, 2024 Cited by PubMed Abstract: The main protease (M) of SARS-CoV-2 is critical in the virus's replication cycle, facilitating the maturation of polyproteins into functional units. Due to its conservation across taxa, M is a promising target for broad-spectrum antiviral drugs. Targeting M with small molecule inhibitors, such as nirmatrelvir combined with ritonavir (Paxlovid™), which the FDA has approved for post-exposure treatment and prophylaxis, can effectively interrupt the replication process of the virus. A key aspect of M's function is its ability to form a functional dimer. However, the mechanics of dimerization and its influence on proteolytic activity remain less understood. In this study, we utilized biochemical, structural, and molecular modelling approaches to explore M dimerization. We evaluated critical residues, specifically Arg4 and Arg298, that are essential for dimerization. Our results show that changes in the oligomerization state of M directly affect its enzymatic activity and dimerization propensity. We discovered a synergistic relationship influencing dimer formation, involving both intra- and intermolecular interactions. These findings highlight the potential for developing allosteric inhibitors targeting M, offering promising new directions for therapeutic strategies. PubMed: 38582483DOI: 10.1016/j.ijbiomac.2024.131392 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.63 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






